Short communication: Feasibility of dengue vaccine to infect different human cell lines: An alternative potency test using HEK293T cells

Detalhes bibliográficos
Autor(a) principal: Carvalho, Renata Faria de
Data de Publicação: 2022
Outros Autores: Quintaes, Lucas de Siqueira Penna, Su, Thaís de Cássia de Souza, Kobayashi, Leticia Mitiko, Nogueira, Ana Cristina Martins de Almeida
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/55891
Resumo: Fundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde. Laboratório de Vacinas Virais. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde. Programa de Pós-graduação em Vigilância Sanitária. Rio de Janeiro, RJ, Brasil.
id CRUZ_8bb0335285da96941e04358b72b94716
oai_identifier_str oai:www.arca.fiocruz.br:icict/55891
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Carvalho, Renata Faria deQuintaes, Lucas de Siqueira PennaSu, Thaís de Cássia de SouzaKobayashi, Leticia MitikoNogueira, Ana Cristina Martins de Almeida2022-12-05T11:49:03Z2022-12-05T11:49:03Z2022CARVALHO, Renata faria de et al. Short communication: Feasibility of dengue vaccine to infect different human cell lines: An alternative potency test using HEK293T cells. Plos One, v. 17, n. 5, e0267653, p. 1 - 14, May 2022.1932-6203https://www.arca.fiocruz.br/handle/icict/5589110.1371/ journal.pone.0267653engPublic Library of ScienceInfectar diferentes linhas celulares humanasTeste alternativo de potênciaUso células HEK293TViabilidade da vacina da DengueFeasibility of dengue vaccineInfect different human cell linesAlternative potency testUsing HEK293T cellsShort communication: Feasibility of dengue vaccine to infect different human cell lines: An alternative potency test using HEK293T cellsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleFundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde. Laboratório de Vacinas Virais. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde. Programa de Pós-graduação em Vigilância Sanitária. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde. Laboratório de Vacinas Virais. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde. Laboratório de Vacinas Virais. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde. Laboratório de Vacinas Virais. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde. Programa de Pós-graduação em Vigilância Sanitária. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ, Brasil.Dengue is caused by an arbovirus that belongs to the Flaviviridae family and there are four distinct, but close related, circulating serotypes. Dengue disease is of great importance for global public health, with vaccination being its main prophylactic measure. However, there is a paucity of biological models for evaluating tetravalent dengue vaccines. The aim of this study was to evaluate the susceptibility of human cell lines HEK293T and THP-1 to a commercial dengue vaccine and test the feasibility of this approach in the development of a potency assay with human cell lines, as a methodological alternative to the golden standard potency assay with VERO cells. In this context, we used a batch of the commercial vaccine Dengvaxia® (CYD-TDV) for the infection tests. We evaluated the presence of the vaccine virus in THP-1 cells, differentiated into macrophages (dTHP-1), and in HEK293T by confocal microscopy, using 4G2 pan-flavivirus antibody. Vaccine infectivity and potency were determined by immunocolorimetric assay using monoclonal antibodies specific for each serotype. The results indicated that the human strain HEK293T was responsive to the tetravalent vaccine, as shown by the presence of virus particles in the cell cytoplasm in a pattern similar to the one observed with VERO cells. Moreover, it was possible to determine the infectivity and potency values of each vaccine virus serotype in the HEK293T, with serotype 4 prevailing over the others. Thus, the human cell line HEK293T provides a potential candidate to be used in assays to determine potency and identity of tetravalent dengue vaccines.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/55891/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALAnaCristinaNogueira_etal_IOC_2022.pdfAnaCristinaNogueira_etal_IOC_2022.pdfapplication/pdf2428994https://www.arca.fiocruz.br/bitstream/icict/55891/2/AnaCristinaNogueira_etal_IOC_2022.pdfa89968b7c0fc43b7edd11b97f9144c90MD52icict/558912023-09-04 10:37:08.747oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-09-04T13:37:08Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.en_US.fl_str_mv Short communication: Feasibility of dengue vaccine to infect different human cell lines: An alternative potency test using HEK293T cells
title Short communication: Feasibility of dengue vaccine to infect different human cell lines: An alternative potency test using HEK293T cells
spellingShingle Short communication: Feasibility of dengue vaccine to infect different human cell lines: An alternative potency test using HEK293T cells
Carvalho, Renata Faria de
Infectar diferentes linhas celulares humanas
Teste alternativo de potência
Uso células HEK293T
Viabilidade da vacina da Dengue
Feasibility of dengue vaccine
Infect different human cell lines
Alternative potency test
Using HEK293T cells
title_short Short communication: Feasibility of dengue vaccine to infect different human cell lines: An alternative potency test using HEK293T cells
title_full Short communication: Feasibility of dengue vaccine to infect different human cell lines: An alternative potency test using HEK293T cells
title_fullStr Short communication: Feasibility of dengue vaccine to infect different human cell lines: An alternative potency test using HEK293T cells
title_full_unstemmed Short communication: Feasibility of dengue vaccine to infect different human cell lines: An alternative potency test using HEK293T cells
title_sort Short communication: Feasibility of dengue vaccine to infect different human cell lines: An alternative potency test using HEK293T cells
author Carvalho, Renata Faria de
author_facet Carvalho, Renata Faria de
Quintaes, Lucas de Siqueira Penna
Su, Thaís de Cássia de Souza
Kobayashi, Leticia Mitiko
Nogueira, Ana Cristina Martins de Almeida
author_role author
author2 Quintaes, Lucas de Siqueira Penna
Su, Thaís de Cássia de Souza
Kobayashi, Leticia Mitiko
Nogueira, Ana Cristina Martins de Almeida
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Carvalho, Renata Faria de
Quintaes, Lucas de Siqueira Penna
Su, Thaís de Cássia de Souza
Kobayashi, Leticia Mitiko
Nogueira, Ana Cristina Martins de Almeida
dc.subject.other.en_US.fl_str_mv Infectar diferentes linhas celulares humanas
Teste alternativo de potência
Uso células HEK293T
Viabilidade da vacina da Dengue
topic Infectar diferentes linhas celulares humanas
Teste alternativo de potência
Uso células HEK293T
Viabilidade da vacina da Dengue
Feasibility of dengue vaccine
Infect different human cell lines
Alternative potency test
Using HEK293T cells
dc.subject.en.en_US.fl_str_mv Feasibility of dengue vaccine
Infect different human cell lines
Alternative potency test
Using HEK293T cells
description Fundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde. Laboratório de Vacinas Virais. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Nacional de Controle de Qualidade em Saúde. Programa de Pós-graduação em Vigilância Sanitária. Rio de Janeiro, RJ, Brasil.
publishDate 2022
dc.date.accessioned.fl_str_mv 2022-12-05T11:49:03Z
dc.date.available.fl_str_mv 2022-12-05T11:49:03Z
dc.date.issued.fl_str_mv 2022
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv CARVALHO, Renata faria de et al. Short communication: Feasibility of dengue vaccine to infect different human cell lines: An alternative potency test using HEK293T cells. Plos One, v. 17, n. 5, e0267653, p. 1 - 14, May 2022.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/55891
dc.identifier.issn.en_US.fl_str_mv 1932-6203
dc.identifier.doi.none.fl_str_mv 10.1371/ journal.pone.0267653
identifier_str_mv CARVALHO, Renata faria de et al. Short communication: Feasibility of dengue vaccine to infect different human cell lines: An alternative potency test using HEK293T cells. Plos One, v. 17, n. 5, e0267653, p. 1 - 14, May 2022.
1932-6203
10.1371/ journal.pone.0267653
url https://www.arca.fiocruz.br/handle/icict/55891
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Public Library of Science
publisher.none.fl_str_mv Public Library of Science
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/55891/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/55891/2/AnaCristinaNogueira_etal_IOC_2022.pdf
bitstream.checksum.fl_str_mv 5a560609d32a3863062d77ff32785d58
a89968b7c0fc43b7edd11b97f9144c90
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813009084081766400

Registros relacionados